EUVIMEDEUVIMED entdecken
Crossref

MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies

Yingrui Wei, Peng Zhou, Naiqiang Weng, Ruiyan Li, Xinjie Zhu iD

ACS Biomaterials Science & Engineering · 2026

DOI: 10.1021/acsbiomaterials.6c00143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Yingrui Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Nanoparticles, B7-H1 Antigen, Antineoplastic Agents. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Natural Science Foundation of Hainan Province, National Natural Science Foundation of China, Fundamental Research Funds for Hainan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanobody-based therapeutics that incorporate multifunctional drug molecules into nanobodies (nanobody−drug conjugates, NDCs) have gained substantial attention as promising therapeutic strategies in biomedicine due to their unique ability to precisely target specific cancer cells. However, the efficacy of NDCs depends on efficient internalization of the antibody−antigen complex to facilitate intracellular drug release in the lysosome, and not all surface antigens suffer from internalization upon antibody binding, posing a significant limitation to the effectiveness of NDCs. To address this gap, we rationally designed and constructed MT3 and anti-PD-L1 nanobody (Nb-PD-L1:KN035) fusion protein that enabled self-assembly into nanoparticles during the expression process. The MT3 domain of MT3-KN035 fusion protein nanoparticles did not interrupt the binding affinity between KN035 and PD-L1. In addition, MT3-KN035 protein nanoparticles not only migrated from the PD-L1-positive cell surface to intracellular lysosomes in vitro but also hold a huge targeting potential for tumor regions in vivo. Meanwhile, MT3-KN035 conjugated multiple aldoxorubicin (hereafter, these conjugates are referred to as MT3-KN035-DOX) via an acidic cleavable linker; MT3-KN035-DOXHigh induced tumor apoptosis and exhibited significant antitumor efficacy via facilitating immune cell infiltrations. This work provides a novel therapeutic strategy via nanobody-mediated target engagement and internalization that achieves synergistic therapeutic efficacy between chemotherapy and immune checkpoint blockade therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesNanoparticlesB7-H1 AntigenAntineoplastic AgentsDoxorubicinAnimalsHumansMiceCell Line, TumorImmunotherapy

Stichwörter der Autor:innen

combination therapiescontrolled releasedrug deliveryimmune checkpoint blockadenanobody−drug conjugate

Substanzen

Single-Domain AntibodiesB7-H1 AntigenCD274 protein, humanAntineoplastic AgentsDoxorubicin

Autor:innen und Institutionen

  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
  • Li Song's Academician Workstation of Hainan University (School of Pharmaceutical Sciences), Hainan University, Sanya 572000, China.
  • School of Biomedical Engineering, Hainan University, Haikou 570228, China.

ORCID-Profile: Xinjie Zhu

Förderung

  • Natural Science Foundation of Hainan Province
  • National Natural Science Foundation of China
  • Fundamental Research Funds for Hainan University

Zitieren

APA

Wei, Y., Zhou, P., Weng, N., Li, R., & Zhu, X. (2026). MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.6c00143

Vancouver

Wei Y, Zhou P, Weng N, Li R, Zhu X. MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.6c00143

BibTeX
@article{Wei2026,
  author = {Wei, Yingrui and Zhou, Peng and Weng, Naiqiang and Li, Ruiyan and Zhu, Xinjie},
  title = {MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies},
  journal = {ACS Biomaterials Science & Engineering},
  year = {2026},
  doi = {10.1021/acsbiomaterials.6c00143}
}
Kostenlos starten →